Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares Issued
Ratios

ARS Pharmaceuticals (SPRY) Long-Term Debt Repayments (2021 - 2022)

Historic Long-Term Debt Repayments for ARS Pharmaceuticals (SPRY) over the last 2 years, with Q4 2022 value amounting to $6.0 million.

  • ARS Pharmaceuticals' Long-Term Debt Repayments rose 51318.23% to $6.0 million in Q4 2022 from the same period last year, while for Sep 2023 it was $6.0 million, marking a year-over-year increase of 6100.59%. This contributed to the annual value of $8.7 million for FY2022, which is 37776.55% up from last year.
  • ARS Pharmaceuticals' Long-Term Debt Repayments amounted to $6.0 million in Q4 2022, which was up 51318.23% from $909000.0 recorded in Q3 2022.
  • ARS Pharmaceuticals' 5-year Long-Term Debt Repayments high stood at $6.0 million for Q4 2022, and its period low was $350000.0 during Q1 2021.